



Catalog Number:	MC11033	Product Type:	Small Molecule
Bio-Activity:	HSP90 inhibitor	CAS #:	75747-14-7
Research Categories:	Angiogenesis, cell death, ubiquitin/proteasome, cellular stress, cancer, infectious disease, neurodegeneration	Chemical Name:	17-(Allylamino)-17-desmethoxygeldanamycin
Solubility:	Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 5 mg/ml).	Molecular Formula:	C ₃₁ H ₄₃ N ₃ O ₈
Purity:	> 99%	Molecular Weight:	585.7
Format:	Powder	Ship Temp:	Ambient
Storage:	Room Temperature		

Application Notes

Description/Data:

Semi-synthetic analog of geldanamycin which is less toxic and more stable [1]. Selectively binds to and inhibits HSP90 from tumor cells displaying a 100-fold higher affinity for tumor cell-derived over normal cell HSP90 [2]. Displays anti-angiogenic activity [3]. Sensitizes tumor cells to apoptosis in response to anticancer agents such as taxol [4]. Induces cytoplasmic α -synuclein aggregate clearance by induction of autophagy [5]. Cell permeable.

References:

- 1) TW Schulte et al. Cancer Chemother. Pharmacol. 1998 42:273
- 2) A Kamal et al. Nature 2003 425:407
- 3) G Kaur et al. Clin. Cancer Res. 2004 10:4813
- 4) DB Solit et al. Cancer Res. 2003 63:2139
- 5) M Riedel et al. PLoS One 2010 5(1):e8753

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012